Investigating the role of a protein in melanoma development and progression
Official title: Role of sirtuin 6 in melanoma development and progression
Funded at Wm S. Middleton Memorial Veterans Hosp · NIH-11183334 · Data updated 2026-11-12
This study is looking at how a protein called SIRT6 affects the growth and spread of melanoma, a serious skin cancer, to find new ways to treat it better for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wm S. Middleton Memorial Veterans Hosp NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | October 1, 2021 |
| Project end | September 30, 2025 |
| Funding year | 2025 |
| NIH project number | 2I01CX002210-05 |
| Project ID | NIH-11183334 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with malignant melanoma, particularly those who have experienced treatment resistance.
✕Less likely to help
Patients with non-melanoma skin cancers or those without a diagnosis of melanoma may not benefit from this research.
What this research studies
This research focuses on understanding how the protein sirtuin 6 (SIRT6) influences the growth and spread of melanoma, a serious skin cancer. Researchers are examining the mechanisms by which SIRT6 contributes to melanoma's resistance to existing treatments and its role in promoting cancer cell proliferation. By using both laboratory and animal models, the study aims to identify new therapeutic strategies that target SIRT6 to improve melanoma management. The findings could lead to the development of innovative treatments that are more effective against this aggressive cancer.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for melanoma patients, potentially overcoming drug resistance and improving survival rates.
How similar studies have gone: Previous research has shown promising results in targeting sirtuins for cancer treatment, indicating that this approach may be effective.
Where this research is happening
-
Wm S. Middleton Memorial Veterans Hosp
Madison, United States Active
Researchers
- Principal investigator: Ahmad, Nihal — Wm S. Middleton Memorial Veterans Hosp
- Study coordinator: Ahmad, Nihal
Related research
Other NIH-funded projects on the same topics.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
SIRT6 and melanoma growth and spread
Researchers are seeing if blocking a protein called SIRT6 can help stop melanoma from growing and spreading in people with melanoma.
-
How tumor cell stress and nearby support cells help melanoma spread
This project looks at whether blocking a tumor cell stress response and changing how nearby support cells behave might keep melanoma cells from surviving, spreading, and resisting treatment.
-
PLK4 as a potential drug target in melanoma
Researchers are exploring whether blocking PLK4 could be a new way to treat melanoma and how PLK4 works with other melanoma-driving pathways.
-
A new lentivector to deliver multiple TCRs for melanoma cell therapy
A new gene-delivery approach aims to boost T cell receptors inside patients’ own cells to treat advanced melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.